188RNL-BAM

DEVELOPMENT STEP phase-2
SPONSOR MATRIX Plus Therapeutics [PSTV]
MECHANISM TARGET // UNMAPPED_TARGET

[THERAPEUTIC_PROFILE]

Target Indications

Primary / Secondary Liver Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer

Mechanism Abstract

Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) is a radioembolization drug designed to treat a variety of solid organ tumors, such as primary liver cancer, hepatocellular carcinoma (HCC), and secondary liver cancer, metastatic colorectal cancer (mCRC).

[CLINICAL_TRIALS_REGISTRY]

// NO_ACTIVE_REGISTRY_STUDIES_FOUND (188RNL-BAM)